Drug
Iruplinalkib clinical trials
Also written FL-006 and WX-0593.
- studies test it
- 11
- open now
- 6
- in phase 3
- 1
- first study started
- 2017
Keep track of what changes. Save the iruplinalkib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
11 studies that test it; most in 2024 (3)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 3 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 2
- Phase 2
- 8
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 6
Qilu Pharmaceutical Co., Ltd. (5) · Tianjin Medical University Cancer Institute and Hospital (2) · Shanghai Pulmonary Hospital, Shanghai, China (1) · Pingping Song (1) · Henan Cancer Hospital (1) · Jinming Yu (1)
Studies
Open first, then newest update. How each study uses iruplinalkib is read from its arms, and is right about nine times in ten.
Testing it · 11
- Iruplinalkib Tablets as Postoperative Adjuvant Therapy in Stage IA ALK-positive NSCLC With High-risk FactorsNot yet recruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT07330076Written as Iruplinalkib tablets
- Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung CancerRecruitingPhase 2Pingping SongNCT05765877Written as WX-0593 Tablets
- Cerebrospinal Fluid Immune Microenvironment Mechanism in Anaplastic Lymphoma Kinase Positive Lung Cancer PatientsNot yet recruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT06697990Written as Iruplinalib
- An Exploratory Study of Efficacy and Safety of Iruplinalkib Tablets in Patients With ROS1 Positive Non-small Cell Lung CancerRecruitingEarly Phase 1Henan Cancer HospitalNCT06436885Written as Iruplinalkib tablets
- Neoadjuvant Therapy With Iruplinalkib for Potentially Resectable ALK Positive NSCLC: A Single Arm, Exploratory TrialNot yet recruitingPhase 2Shanghai Pulmonary Hospital, Shanghai, ChinaNCT06282536Written as Iruplinalkib
- WX-0593 Combined With Concurrent Chemoradiotherapy in Unresectable Locally Advanced NSCLCRecruitingPhase 2Jinming YuNCT05351320Written as WX-0593 Tablets
- Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) PatientsActive, not recruitingPhase 3Qilu Pharmaceutical Co., Ltd.NCT04632758Written as WX-0593 Tablets
- Study to Investigate the Efficacy and Safety of WX-0593 in ALK Positive Non-Small Cell Lung Cancer (NSCLC) PatientsStatus unknownPhase 2Qilu Pharmaceutical Co., Ltd.NCT05801107Written as WX-0593
- Single Dose Mass Balance Study With [14C]Iruplinalkib (WX-0593) In Healthy Male VolunteersCompletedPhase 1Qilu Pharmaceutical Co., Ltd.NCT05716126Written as [14C]Iruplinalkib (WX-0593)
- A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung CancerStatus unknownPhase 2Qilu Pharmaceutical Co., Ltd.NCT04641754Written as WX-0593 Tablets
- A Study Evaluates the Safety, Pharmacokinetics and Efficacy of WX-0593 in Advanced Solid Tumor PatientsStatus unknownPhase 1/2Qilu Pharmaceutical Co., Ltd.NCT03389815Written as WX-0593 Tablets
Codes
What other systems call iruplinalkib · ClinicalTrials.gg INT018654
- UNII (FDA) Z5F65W1YAZIRUPLINALKIBOne source FDA
- NCI Thesaurus C154279IruplinalkibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | Z5F65W1YAZ | IRUPLINALKIB | One source FDA |
| NCI Thesaurus | C154279 | Iruplinalkib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.